Company Overview and News
Shares of Kansas City Southern (KSU - Free Report) scaled a 52-week high of $120.34 during the trading session on Aug 29 before retracing a bit to close at $119.46. The prime reason behind this stock price surge can be attributed to the recent agreement between the United States and Mexico to rework the NAFTA (North American Free Trade Agreement) deal, thus putting speculations to rest, which were rife over the United States pulling out of NAFTA.
GATX SKYW GMTA TRN GMT KSU
Alaska Air Group, Inc.’s (ALK - Free Report) wholly owned subsidiary Alaska Airlines has announced a new daily non-stop service between Seattle-Tacoma International Airport and John Glenn Columbus International Airport in Ohio. Operations on the route are expected to begin Mar 7, next year. Notably, this non-stop service would be the only one operating between the Pacific Northwest and Central Ohio.
GATX SKYW GMTA TRN ALK GMT
CHICAGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- GATX Corporation (NYSE:GATX) today announced that Thomas A. Ellman, executive vice president and chief financial officer, will present at the Cowen Global Transportation Conference on Wednesday, September 5, 2018. The presentation will include an overview of GATX’s operations.
GATX GMTA GMT
Shares of Canadian Pacific Railway Limited (CP - Free Report) hit a 52-week high of $208.33 during the trading session on Aug 27 before retracing a bit to close at $207.69. Moreover, the stock has surged 35.2% in a year, outperforming the industry’s 33.7% growth.
GATX CP CP WCN REGN SKYW GMTA TRN GMT
We have issued an updated research report on JetBlue Airways Corporation (JBLU - Free Report) on Aug 27. Due to multiple headwinds, shares of the company have declined 16.7% on a year-to-date basis compared with the industry’s fall of 14.8%.
GATX ECR AAWW SKYW JBLU LMHA GMTA LMHB GMT LM
Per Reuters, Ryanair Holdings PLC (RYAAY - Free Report) has finally given in to the Irish pilots’ demand, reaching an agreement with the pilots’ union (Fórsa) on Aug 23, following a 22-hour discussion. Post the event, shares of the company have been flying high and closed Friday’s trading session at $99.62, up 1.5%. Ryanair has been grappling with labor unrest since the past few months. The issue caused several flight cancellations during the peak summer season, affecting average fares in turn.
GATX SKYW RYAOF RYAAY GMTA TRN GMT
Golar LNG Limited (GLNG - Free Report) posted lower-than-expected results in the second quarter of 2018. It incurred wider-than-expected loss (excluding 74 cents from non-recurring items) of 38 cents. The Zacks Consensus Estimate for the same stood at 19 cents. However, the amount of loss narrowed significantly from 51 cents a year ago. Total operating revenues of $59.4 million also missed the Zacks Consensus Estimate of $63.
GATX SKYW GLNG GMTA TRN GMT
Canadian National Railway Company (CNI - Free Report) has been thriving on the back of impressive freight demand. Let’s delve deeper into the scenario. Canadian National performed well in the second quarter of 2018 buoyed by robust freight demand. The company reported better-than- expected earnings and revenues. Both metrics also improved year over year. While freight revenues increased 10% in the period, growth was witnessed across most key divisions of the company.
GATX TXN SKYW GMTA TRN GMT
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET